These 5 smallcap pharmaceuticals have climbed upto over 160% this month

SUMMARY

In the last one month, smallcap pharmaceutical stocks have been showing a good run despite the coronavirus outbreak. China being the biggest supplier of raw materials to the Indian domestic pharma market has not affected some of these stocks that have climbed up to 160 percent. However, the scenario stands completely different for the largecaps that are currently witnessing a panic sell-off. Let's look into smallcap pharmaceuticals' that have outperformed largecaps in the month of February:

By Mousumi Paul Feb 27, 2020 3:13:45 PM IST (Published)

1. Suven Life Sciences is a smallcap pharmaceutical company based in Hyderabad. The stock gave its shareholders whopping returns of 166 percent within a month. The company's December quarter earnings improved, with revenue up 32 percent YoY. Net loss came in at Rs 4.5 crore as compared to Rs 8.31 crore last year.

2. The Karnataka-based smallcap active pharma ingredient (API) manufacturer Shilpa Medicare in the last one month surged over 74 percent. The company's earnings in the December quarter remained strong and healthy with net revenue up 38 percent YoY and net profit rallied 261 percent YoY.

3. Lasa Supergenerics is a smallcap pharmaceutical company involved in veterinary API that rose over 56 percent in the month of February. The recent quarterly earnings of the company remained stable. The net revenue declined 27 percent YoY but the net profit came in at Rs 2.57 crore as against the net loss of Rs 5.27 crore in the same quarter last year.

4. Chennai-based Solara Active Pharma Sciences is an API manufacturer that has rallied 54 percent in the last one month. The company in its recent quarterly earnings reported a 3.52 percent YoY decline in its net revenue. The net profit of the company, however, saw a jump of 87 percent YoY due to lower expenses.

5. Granules India is into specialty products along with API. Last month, the stock surged 23 percent. In December quarter, the company reported a healthy set of earnings with its net revenue and profit rising 11 percent YoY and 6 percent YoY respectively.